No Data
No Data
VBI Vaccines Shows Promise in Glioblastoma Trial
Express News | VBI Vaccines Inc: Expect to Have Additional Tumor Response Data and Initial Survival Data Throughout Remainder of 2024
Express News | VBI Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2B Study of VBI-1901 in Recurrent Glioblastoma Patients
VBI Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company's immunotherapeutic cancer vaccine candidate, in recurrent glioblastoma (rGBM) patients.
VBI Vaccines' Promising Glioblastoma Treatment Data
VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data From VBI-1901 in Recurrent Glioblastoma Patients
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company's cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), were accepted for poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.